Niclosamide from an anthelmintic drug to a promising adjuvant therapy for diabetic kidney disease: randomized clinical trial

Table 3 Summary of the secondary outcomes

	Niclosamide arm n = 30	Control arm n = 30	P value between arms
MMP-7 (ng/mL)
Baseline	7.8 ± 1.4	7.4 ± 2	0.41
After 6 months	6.1 ± 1.1	8.1 ± 1.6	0.0001*
Percent change between the 2 points	− 22 ± 10	16 ± 36	< 0.0001*
P Value within each arm	< 0.0001*	0.003*
PCX (ng/mL)
Baseline	9.7 ± 5.2	9.5 ± 3.4	0.89
After 6 months	7.8 ± 3	10.9 ± 4.1	0.002*
Percent change between the 2 points	− 2 ± 53	15 ± 20	0.094
P Value within each arm	0.044*	0.001*
8-OHdG (ng/mL)
Baseline	34.3 ± 6.2	36.3 ± 7.3	0.27
After 6 months	38.4 ± 11.7	39.7 ± 9.8	0.66
Percent change between the 2 points	13 ± 36	12 ± 30	0.84
P Value within each arm	0.055	0.067

Values are expressed as mean ± SD
MMP-7 matrix metalloproteinase-7, PCX podocalyxin, 8-OHdG 8-hydroxy-2ʹ-deoxyguanosine
*Significant difference (P < 0.05)

ISSN: 1758-5996